All News
One-Third Rheumatoid Risk from Lifestyle
Analysis of the NHANES (National Health and Nutrition Examination Survey) data suggests that one-third of the risk of developing rheumatoid arthritis (RA) in the USA is attributable smoking, obesity and alcohol intake.
Read Article
French study of 782 men (50-85 years) with DISH found DISH was associated with increased vertebral fractures (OR 2.89; 95% CI, 1.15-7.28; P <.05), but Nonvertebral fractures were not associated with DISH (HR 0.72; 0.33-1.56). https://t.co/YoQ8r62pns
Links:
Dr. John Cush RheumNow ( View Tweet)
British registry 801 axial SpA pts; 646 did not hve fibromyalgia at baseline & 46 (7%) developed FM over time. Of 115 axSpa w/ baseline FM, 77 (2/3) recovered. FM more likely with high Dz activity ((OR 1.27) & widespread pain (OR 1.14) https://t.co/4jOdaXIJuB https://t.co/ruOYj5HmMX
Links:
Dr. John Cush RheumNow ( View Tweet)
Our Top January Tweet:
Urate Lowering Therapy During Acute Gout
Acute gout has its well-defined protocols, and most state that urate lowering therapy should be continued; but does ULT affect outcomes in an acute gout attack?
https://t.co/aDHpU1qrlu https://t.co/6xDwyVjuyC
Links:
Dr. John Cush RheumNow ( View Tweet)
Multiple intraarticular steroid injxs NO better than placebo. Analysis of 6 RCTs show no diff in pain than PBO (−0.47, 95% CI −0.62, 0.31). 14 RCTs + 2 Observ. studies show IA steroids may cause mor cartilage loss or risk of joint replacement (HR 2.54) https://t.co/jCLq4jWn4Y
Links:
Dr. John Cush RheumNow ( View Tweet)
Everyone longs for normal. Normal may have changed, died, or been put off. But tomorrow morning, normal is waking up and looking to you for guidance
Dr. John Cush RheumNow ( View Tweet)
Sign up for RheumNow Live, March 20 and 21st. CME credits available.
https://t.co/uwxOVh142F https://t.co/GqkCLBGl62
Links:
Dr. John Cush RheumNow ( View Tweet)
Download our latest resource--Televideo Joint Exam Checklist.
https://t.co/XnyCW2eak8
Links:
Dr. John Cush RheumNow ( View Tweet)
The RheumNow podcast is now up--listen in on SoundCloud, RheumNow or Apple/Android car play.
Rheumatology Burnout?--Dr. Cush reviews the top articles from the week of 1/29/21.
https://t.co/HiX7qMFU6b https://t.co/KbaZ6XjHG6
Links:
Dr. John Cush RheumNow ( View Tweet)
Calculating Serious Infection Risk in IMID Patients
Predictive modeling of data derived from the DANBIO registry (of treated IMID patients) revealed a 4 fold increased risk of serious infection in those starting biologic DMARD treatment.
Read more: https://t.co/i2GwiCvCx6 https://t.co/9sZ79LyZ7u
Links:
Dr. John Cush RheumNow ( View Tweet)
High Placebo Responses in SLE Trials
A systematic review in randomized controlled trials (RCTs) of non-renal, non-neuropsychiatric systemic lupus erythematosus (SLE) patients showing unexpectedly high placebo responses.
Read more: https://t.co/zUPsVFEz4n https://t.co/Gk7ke4hBwY
Links:
Dr. John Cush RheumNow ( View Tweet)
QD Clinic Podcast for the week of Jan 29 - Pearls from Practice This wk:
Arthritis &Crohn's
Rhabdo or Not
Dadgummit, Where's Waldos COVID Vaccine?
"I Don't Know"
A Tale of Two Gouts
https://t.co/7ndYSOgh5R or listen on iTunes https://t.co/FHJv01AAbC https://t.co/780P7Bdw8F
Dr. John Cush RheumNow ( View Tweet)
RheumNow Podcast is up - Rheumatology Burnout (1.29.2021) - Vaccine #s, Colchicine in COVID, Rheums #2 in Burnout? Endometriosis & RA risk, Comorbidity as predictors. https://t.co/HiX7qMFU6b or listen on iTunes>>https://t.co/FHJv01AAbC or on SoundCloud>> https://t.co/0BfqGhxgQj https://t.co/j9nHMs4C6d
Dr. John Cush RheumNow ( View Tweet)
Lupus Nephritis Despite Low Level Proteinuria
https://t.co/awxvsvwGTg https://t.co/e6DV6sfiN5
Links:
Dr. John Cush RheumNow ( View Tweet)
2016 Deloitte report on top 10 healthcare innovations (Spot on!):
1 Next gen sequencing
2 3-D printing
3 AI
4 Immunotherapy
5 Point of care diagnostics
6 virtual reality
7 social media for Pts
8 Biosensors/trackers
9 Telehealth
10 Convenient care https://t.co/yWaqzM9pFC
Links:
Dr. John Cush RheumNow ( View Tweet)
ACR Convergence 2020 Fireside Chats – Top presentations in nr-axSpA, AS, axial PsA
Sponsored by Novartis Medical Affairs
Unable to attend all the key sessions at #ACR20? Listen to the experts as they present their views on the top abstracts.
https://t.co/r5Cf4WS63s https://t.co/NmDXrTPGXq
Links:
Dr. John Cush RheumNow ( View Tweet)
Several studies have shown that Xray progression has lessened in recent yrs - presumeably from more aggressive Rx by Rheums! Still - Predictors of Xray long term damage = high ESR/CRP, baseline xray damage, -CCP/RF positivity https://t.co/2iaMiaquEV https://t.co/cgEP4QBvL4
Dr. John Cush RheumNow ( View Tweet)
JAK Inhibitor Misses Endpoint in Safety Study. Now What?
Pfizer announced results Wednesday from its FDA-mandated postmarketing safety study of tofacitinib (Xeljanz), and they don't bode well for the drug and possibly others in its class.
https://t.co/EPVdAdPP37 https://t.co/Box5NaxsKV
Links:
Dr. John Cush RheumNow ( View Tweet)
News: #COVID19 risk may be reduced with #biologics and #JAKinhibitors, but increased with #glucocorticoids, Italian researchers report in @ArthritisRes https://t.co/zIef2aNCns
Medicine Matters rheumatology Rheum_Matters ( View Tweet)
SELECT-PsA2, UPA vs PLBO in refractory PsA, @ARD_BMJ
Better ACR20 (57% vs 24% PLBO, NNT~3) and ACR50 (32% vs 5% PLBO, NNT~4). Decent PASI 90 (30% vs 6%, NNT~4)
Similar adverse events to RA pop. Nice to have another option, esp in refractory dx! https://t.co/Zz2WYqswT2
Mike Putman EBRheum ( View Tweet)